Endotoxin Challenge Study For Healthy Men and Women

• Status: Completed
• Trial end date: 2008-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data from this study will be used to support GSK256066 dose selection for future studies in COPD patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide

Criteria

Inclusion Criteria:

• Healthy males and females (contraception restrictions),

• 18-50yrs,

• BMI 19-31kg/m2,

• Non-smokers,

• FEV1 >/= 80% predicted

Exclusion Criteria:

• Abnormal troponin and/or CK MB,

• Participated in any GSK study involving the administration of COA for >/= 21 days.